25 XP 0   0   10  
0coffee
Main menu
3rd party ad coffee SUPPORTERis ad-free.

AKYA (Akoya Biosciences Inc) Stock Analysis
Buy, Hold or Sell?

Let's analyze Akoya Biosciences Inc together

I guess you are interested in Akoya Biosciences Inc. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

  • 📊 Fundamental Analysis (FA) – Akoya Biosciences Inc’s Financial Insights
  • 📈 Technical Analysis (TA) – Akoya Biosciences Inc’s Price Targets

I'm going to help you getting a better view of Akoya Biosciences Inc. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

Get notifications about Akoya Biosciences Inc

I send you an email if I find something interesting about Akoya Biosciences Inc.

1. Quick Overview

1.1. Quick analysis of Akoya Biosciences Inc (30 sec.)










1.2. What can you expect buying and holding a share of Akoya Biosciences Inc? (30 sec.)

How much money do you get?

How much money do you get?
$0.00
When do you have the money?
1 year
How often do you get paid?
23.8%

What is your share worth?

Current worth
$-0.12
Expected worth in 1 year
$-0.89
How sure are you?
14.3%

+ What do you gain per year?

Total Gains per Share
$-0.77
Return On Investment
-59.9%

For what price can you sell your share?

Current Price per Share
$1.29
Expected price per share
$1.09 - $1.44
How sure are you?
50%
3rd party ad coffee SUPPORTERis ad-free.

2. Detailed Analysis

2.1. Valuation of Akoya Biosciences Inc (5 min.)




Live pricePrice per Share (EOD)
$1.29
Intrinsic Value Per Share
$3.32 - $4.44
Total Value Per Share
$3.20 - $4.32

2.2. Growth of Akoya Biosciences Inc (5 min.)




Is Akoya Biosciences Inc growing?

Current yearPrevious yearGrowGrow %
How rich?-$5.8m$55m-$45.6m-486.3%

How much money is Akoya Biosciences Inc making?

Current yearPrevious yearGrowGrow %
Making money-$11.8m-$17m$5.1m43.1%
Net Profit Margin-61.3%-77.1%--

How much money comes from the company's main activities?

2.3. Financial Health of Akoya Biosciences Inc (5 min.)




2.4. Comparing to competitors in the Medical Instruments & Supplies industry (5 min.)




  Industry Rankings (Medical Instruments & Supplies)  


Richest
#156 / 159

Most Revenue
#109 / 159

Most Profit
#137 / 159

Most Efficient
#134 / 159
3rd party ad coffee SUPPORTERis ad-free.

3. Summary and Key Metrics

3.1. What can you expect buying and holding a share of Akoya Biosciences Inc?

Welcome investor! Akoya Biosciences Inc's management wants to use your money to grow the business. In return you get a share of Akoya Biosciences Inc.

First you should know what it really means to hold a share of Akoya Biosciences Inc. And how you can make/lose money.

Speculation

The Price per Share of Akoya Biosciences Inc is $1.29. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Akoya Biosciences Inc.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Akoya Biosciences Inc, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $-0.12. Based on the TTM, the Book Value Change Per Share is $-0.19 per quarter. Based on the YOY, the Book Value Change Per Share is $-0.05 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Akoya Biosciences Inc.

How much money are you going to get?

 MRQTTMYOY3Y5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps-0.31-24.3%-0.24-18.4%-0.34-26.4%-0.31-24.4%-0.27-20.8%-0.26-20.0%
Usd Book Value Change Per Share-0.27-20.9%-0.19-15.0%-0.05-3.6%-0.19-14.5%-0.01-0.5%-0.01-0.4%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.010.4%0.010.4%
Usd Total Gains Per Share-0.27-20.9%-0.19-15.0%-0.05-3.6%-0.19-14.5%0.000.0%0.000.0%
Usd Price Per Share1.39-2.19-5.40-6.06-6.62-6.30-
Price to Earnings Ratio-1.11--2.51--4.27--4.69--6.50--6.19-
Price-to-Total Gains Ratio-5.15--12.76--12.96--19.57--24.83--24.83-
Price to Book Ratio-11.79-4.62-5.14-5.98-4.74-4.52-
Price-to-Total Gains Ratio-5.15--12.76--12.96--19.57--24.83--24.83-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share1.29
Number of shares775
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.01
Usd Book Value Change Per Share-0.19-0.01
Usd Total Gains Per Share-0.190.00
Gains per Quarter (775 shares)-149.76-0.28
Gains per Year (775 shares)-599.03-1.11
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10-599-60917-18-11
20-1198-120834-37-12
30-1797-180751-55-13
40-2396-240669-73-14
50-2995-300586-91-15
60-3594-3604103-110-16
70-4193-4203120-128-17
80-4792-4802137-146-18
90-5391-5401154-164-19
100-5990-6000172-183-20

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.04.00.00.0%0.012.00.00.0%0.020.00.00.0%0.021.00.00.0%0.021.00.00.0%
Book Value Change Per Share0.04.00.00.0%1.011.00.08.3%3.015.02.015.0%3.015.03.014.3%3.015.03.014.3%
Dividend per Share0.00.04.00.0%1.00.011.08.3%5.00.015.025.0%5.00.016.023.8%5.00.016.023.8%
Total Gains per Share0.04.00.00.0%1.011.00.08.3%3.015.02.015.0%3.015.03.014.3%3.015.03.014.3%
3rd party ad coffee SUPPORTERis ad-free.

3.2. Key Performance Indicators

The key performance indicators of Akoya Biosciences Inc compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-3Y+/-5 Year+/-10 Year+/-
Book Value Change Per Share---0.270-0.193-28%-0.047-83%-0.188-31%-0.006-98%-0.006-98%
Book Value Per Share---0.1180.188-163%1.103-111%0.875-113%0.997-112%0.950-112%
Current Ratio--0.6132.175-72%3.295-81%2.895-79%3.187-81%3.035-80%
Debt To Asset Ratio--1.0520.933+13%0.690+52%0.747+41%0.645+63%0.615+71%
Debt To Equity Ratio---7.363-100%2.393-100%3.839-100%2.570-100%2.448-100%
Dividend Per Share----0%-0%0.000-100%0.006-100%0.005-100%
Enterprise Value---21557662.00026629927.000-181%228814565.500-109%251975695.000-109%387308603.750-106%387308603.750-106%
Eps---0.313-0.238-24%-0.340+9%-0.315+0%-0.268-15%-0.258-18%
Ev To Ebitda Ratio--0.402-1.120+379%-5.347+1431%-4.963+1335%-10.823+2793%-10.823+2793%
Ev To Sales Ratio---0.3240.307-206%2.468-113%3.073-111%5.734-106%5.734-106%
Free Cash Flow Per Share---0.148-0.162+9%-0.278+87%-0.251+69%-0.218+47%-0.210+42%
Free Cash Flow To Equity Per Share---0.154-0.177+15%0.006-2667%-0.114-26%0.009-1811%0.004-4176%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%1.0000%1.0000%
Intrinsic Value_10Y_max--4.439----------
Intrinsic Value_10Y_min--3.318----------
Intrinsic Value_1Y_max---0.794----------
Intrinsic Value_1Y_min---0.781----------
Intrinsic Value_3Y_max---1.442----------
Intrinsic Value_3Y_min---1.396----------
Intrinsic Value_5Y_max---0.952----------
Intrinsic Value_5Y_min---0.965----------
Market Cap64440918.000-8%69436338.000109149927.000-36%269877565.500-74%302639195.000-77%330447033.000-79%314711460.000-78%
Net Profit Margin---0.941-0.613-35%-0.771-18%-0.769-18%-0.733-22%-0.707-25%
Operating Margin---0.352-0.372+6%-0.668+90%-0.629+79%-0.625+78%-0.602+71%
Operating Ratio--1.7971.496+20%1.603+12%1.654+9%1.611+12%1.595+13%
Pb Ratio-10.943+7%-11.7914.623-355%5.144-329%5.984-297%4.744-349%4.518-361%
Pe Ratio-1.029+7%-1.109-2.511+126%-4.267+285%-4.688+323%-6.501+486%-6.192+458%
Price Per Share1.290-8%1.3902.185-36%5.403-74%6.058-77%6.615-79%6.300-78%
Price To Free Cash Flow Ratio-2.172+7%-2.340-3.890+66%-5.896+152%-6.252+167%-6.910+195%-6.581+181%
Price To Total Gains Ratio-4.779+7%-5.150-12.756+148%-12.962+152%-19.570+280%-24.826+382%-24.826+382%
Quick Ratio--0.4302.112-80%3.015-86%2.772-84%2.933-85%2.794-85%
Return On Assets---0.139-0.094-32%-0.099-29%-0.100-28%-0.082-41%-0.078-44%
Return On Equity----0.6110%-0.3540%-0.4220%-0.3020%-0.2910%
Total Gains Per Share---0.270-0.193-28%-0.047-83%-0.188-31%0.000-100%0.000-100%
Usd Book Value---5889000.0009397000.000-163%55091750.000-111%43716500.000-113%49814250.000-112%47442142.857-112%
Usd Book Value Change Per Share---0.270-0.193-28%-0.047-83%-0.188-31%-0.006-98%-0.006-98%
Usd Book Value Per Share---0.1180.188-163%1.103-111%0.875-113%0.997-112%0.950-112%
Usd Dividend Per Share----0%-0%0.000-100%0.006-100%0.005-100%
Usd Enterprise Value---21557662.00026629927.000-181%228814565.500-109%251975695.000-109%387308603.750-106%387308603.750-106%
Usd Eps---0.313-0.238-24%-0.340+9%-0.315+0%-0.268-15%-0.258-18%
Usd Free Cash Flow---7418000.000-8085750.000+9%-13897750.000+87%-12523500.000+69%-10914950.000+47%-10507238.095+42%
Usd Free Cash Flow Per Share---0.148-0.162+9%-0.278+87%-0.251+69%-0.218+47%-0.210+42%
Usd Free Cash Flow To Equity Per Share---0.154-0.177+15%0.006-2667%-0.114-26%0.009-1811%0.004-4176%
Usd Market Cap64440918.000-8%69436338.000109149927.000-36%269877565.500-74%302639195.000-77%330447033.000-79%314711460.000-78%
Usd Price Per Share1.290-8%1.3902.185-36%5.403-74%6.058-77%6.615-79%6.300-78%
Usd Profit---15652000.000-11883250.000-24%-17001250.000+9%-15715166.667+0%-13123950.000-16%-12601047.619-19%
Usd Revenue--16639000.00019990250.000-17%23393250.000-29%21075750.000-21%17807100.000-7%17483952.381-5%
Usd Total Gains Per Share---0.270-0.193-28%-0.047-83%-0.188-31%0.000-100%0.000-100%
 EOD+2 -6MRQTTM+11 -25YOY+12 -243Y+12 -265Y+9 -2910Y+9 -29

3.3 Fundamental Score

Let's check the fundamental score of Akoya Biosciences Inc based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-1.029
Price to Book Ratio (EOD)Between0-1-10.943
Net Profit Margin (MRQ)Greater than0-0.941
Operating Margin (MRQ)Greater than0-0.352
Quick Ratio (MRQ)Greater than10.430
Current Ratio (MRQ)Greater than10.613
Debt to Asset Ratio (MRQ)Less than11.052
Debt to Equity Ratio (MRQ)Less than10.000
Return on Equity (MRQ)Greater than0.150.000
Return on Assets (MRQ)Greater than0.05-0.139
Total1/10 (10.0%)

3.4 Technical Score

Let's check the technical score of Akoya Biosciences Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
OpenGreater thanClose1.290
Total0/1 (0.0%)

4. In-depth Analysis

4.1 About Akoya Biosciences Inc

Akoya Biosciences, Inc., a life sciences technology company, provides spatial biology solutions for transforming discovery, clinical research, and diagnostics in North America, the Asia-Pacific, Europe, the Middle East, and Africa. The company offers PhenoCycler instrument, a compact bench-top fluidics system that integrates with a companion microscope to automate image acquisition; and PhenoImager platform that enables researchers to visualize, analyze, quantify, and phenotype cells in situ, in fresh frozen or formalin-fixed paraffin-embedded tissue sections, and tissue microarrays utilizing an automated and high-throughput workflow. It also provides PhenoCycler and PhenoImager reagents; and biopharma services. In addition, the company offers analysis software partnerships ecosystem; inForm Tissue, an automated image analysis software package for accurately visualizing and quantifying biomarkers in tissue sections; Phenoptr, which provides functions that consolidate and analyze output tables created by inForm software; and phenoptrReports, a software that generates shareable reports and visualizations based on the phenoptr output in an intuitive front-end GUI. Akoya Biosciences, Inc. was incorporated in 2015 and is headquartered in Marlborough, Massachusetts.

Fundamental data was last updated by Penke on 2025-07-10 20:13:03.

4.2 In-depth Summary

4.2.1. Financial Health Summary

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very inefficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is just able to pay all its debts by selling its assets.
The company is unable to pay all its debts with equity.

4.2.2. Valuation Summary

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is fair priced.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.
3rd party ad coffee SUPPORTERis ad-free.

4.3 Financial Health

4.3.1. Profitability

4.3.1 Profitability
4.3.1.1. Net Profit Margin

Measures how much net profit Akoya Biosciences Inc earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Akoya Biosciences Inc to the Medical Instruments & Supplies industry mean.
  • A Net Profit Margin of -94.1% means that $-0.94 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Akoya Biosciences Inc:

  • The MRQ is -94.1%. The company is making a huge loss. -2
  • The TTM is -61.3%. The company is making a huge loss. -2
Trends
Current periodCompared to+/- 
MRQ-94.1%TTM-61.3%-32.8%
TTM-61.3%YOY-77.1%+15.8%
TTM-61.3%5Y-73.3%+11.9%
5Y-73.3%10Y-70.7%-2.6%
Compared to industry (Medical Instruments & Supplies)
PeriodCompanyIndustry (mean)+/- 
MRQ-94.1%5.0%-99.1%
TTM-61.3%4.7%-66.0%
YOY-77.1%6.5%-83.6%
3Y-76.9%6.4%-83.3%
5Y-73.3%6.1%-79.4%
10Y-70.7%6.6%-77.3%
4.3.1.2. Return on Assets

Shows how efficient Akoya Biosciences Inc is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Akoya Biosciences Inc to the Medical Instruments & Supplies industry mean.
  • -13.9% Return on Assets means that Akoya Biosciences Inc generated $-0.14 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Akoya Biosciences Inc:

  • The MRQ is -13.9%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -9.4%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-13.9%TTM-9.4%-4.5%
TTM-9.4%YOY-9.9%+0.4%
TTM-9.4%5Y-8.2%-1.2%
5Y-8.2%10Y-7.8%-0.4%
Compared to industry (Medical Instruments & Supplies)
PeriodCompanyIndustry (mean)+/- 
MRQ-13.9%1.0%-14.9%
TTM-9.4%1.0%-10.4%
YOY-9.9%1.0%-10.9%
3Y-10.0%1.2%-11.2%
5Y-8.2%1.5%-9.7%
10Y-7.8%1.5%-9.3%
4.3.1.3. Return on Equity

Shows how efficient Akoya Biosciences Inc is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Akoya Biosciences Inc to the Medical Instruments & Supplies industry mean.
  • 0.0% Return on Equity means Akoya Biosciences Inc generated $0.00 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Akoya Biosciences Inc:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-61.1%+61.1%
TTM-61.1%YOY-35.4%-25.7%
TTM-61.1%5Y-30.2%-30.8%
5Y-30.2%10Y-29.1%-1.1%
Compared to industry (Medical Instruments & Supplies)
PeriodCompanyIndustry (mean)+/- 
MRQ-2.2%-2.2%
TTM-61.1%1.9%-63.0%
YOY-35.4%1.8%-37.2%
3Y-42.2%2.1%-44.3%
5Y-30.2%3.0%-33.2%
10Y-29.1%2.9%-32.0%
3rd party ad coffee SUPPORTERis ad-free.

4.3.2. Operating Efficiency of Akoya Biosciences Inc.

4.3.2. Operating Efficiency
4.3.2.1. Operating Margin

Measures how efficient Akoya Biosciences Inc is operating .

  • Measures how much profit Akoya Biosciences Inc makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Akoya Biosciences Inc to the Medical Instruments & Supplies industry mean.
  • An Operating Margin of -35.2% means the company generated $-0.35  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Akoya Biosciences Inc:

  • The MRQ is -35.2%. The company is operating very inefficient. -2
  • The TTM is -37.2%. The company is operating very inefficient. -2
Trends
Current periodCompared to+/- 
MRQ-35.2%TTM-37.2%+2.0%
TTM-37.2%YOY-66.8%+29.6%
TTM-37.2%5Y-62.5%+25.4%
5Y-62.5%10Y-60.2%-2.3%
Compared to industry (Medical Instruments & Supplies)
PeriodCompanyIndustry (mean)+/- 
MRQ-35.2%8.0%-43.2%
TTM-37.2%6.0%-43.2%
YOY-66.8%6.0%-72.8%
3Y-62.9%6.7%-69.6%
5Y-62.5%8.7%-71.2%
10Y-60.2%9.0%-69.2%
4.3.2.2. Operating Ratio

Measures how efficient Akoya Biosciences Inc is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Medical Instruments & Supplies industry mean).
  • An Operation Ratio of 1.80 means that the operating costs are $1.80 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Akoya Biosciences Inc:

  • The MRQ is 1.797. The company is inefficient in keeping operating costs low. -1
  • The TTM is 1.496. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ1.797TTM1.496+0.301
TTM1.496YOY1.603-0.107
TTM1.4965Y1.611-0.116
5Y1.61110Y1.595+0.016
Compared to industry (Medical Instruments & Supplies)
PeriodCompanyIndustry (mean)+/- 
MRQ1.7971.168+0.629
TTM1.4961.131+0.365
YOY1.6031.023+0.580
3Y1.6541.084+0.570
5Y1.6111.053+0.558
10Y1.5951.016+0.579
3rd party ad coffee SUPPORTERis ad-free.

4.4.3. Liquidity of Akoya Biosciences Inc.

4.4.3. Liquidity
4.4.3.1. Current Ratio

Measures if Akoya Biosciences Inc is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Medical Instruments & Supplies industry mean).
  • A Current Ratio of 0.61 means the company has $0.61 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Akoya Biosciences Inc:

  • The MRQ is 0.613. The company is unable to pay all its short-term debts. -2
  • The TTM is 2.175. The company is able to pay all its short-term debts. +1
Trends
Current periodCompared to+/- 
MRQ0.613TTM2.175-1.562
TTM2.175YOY3.295-1.120
TTM2.1755Y3.187-1.012
5Y3.18710Y3.035+0.152
Compared to industry (Medical Instruments & Supplies)
PeriodCompanyIndustry (mean)+/- 
MRQ0.6132.053-1.440
TTM2.1752.039+0.136
YOY3.2952.318+0.977
3Y2.8952.380+0.515
5Y3.1872.609+0.578
10Y3.0352.576+0.459
4.4.3.2. Quick Ratio

Measures if Akoya Biosciences Inc is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Akoya Biosciences Inc to the Medical Instruments & Supplies industry mean.
  • A Quick Ratio of 0.43 means the company can pay off $0.43 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Akoya Biosciences Inc:

  • The MRQ is 0.430. The company is just not able to pay all its short-term debts with the most liquid assets. -1
  • The TTM is 2.112. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ0.430TTM2.112-1.682
TTM2.112YOY3.015-0.904
TTM2.1125Y2.933-0.822
5Y2.93310Y2.794+0.140
Compared to industry (Medical Instruments & Supplies)
PeriodCompanyIndustry (mean)+/- 
MRQ0.4300.835-0.405
TTM2.1120.948+1.164
YOY3.0151.090+1.925
3Y2.7721.201+1.571
5Y2.9331.425+1.508
10Y2.7941.556+1.238
3rd party ad coffee SUPPORTERis ad-free.

4.5.4. Solvency of Akoya Biosciences Inc.

4.5.4. Solvency
4.5.4.1. Debt to Asset Ratio

Measures how much % of Akoya Biosciences Inc assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Akoya Biosciences Inc to Medical Instruments & Supplies industry mean.
  • A Debt to Asset Ratio of 1.05 means that Akoya Biosciences Inc assets are financed with 105.2% credit (debt) and the remaining percentage (100% - 105.2%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Akoya Biosciences Inc:

  • The MRQ is 1.052. The company is just not able to pay all its debts by selling its assets. -1
  • The TTM is 0.933. The company is just able to pay all its debts by selling its assets.
Trends
Current periodCompared to+/- 
MRQ1.052TTM0.933+0.119
TTM0.933YOY0.690+0.243
TTM0.9335Y0.645+0.287
5Y0.64510Y0.615+0.031
Compared to industry (Medical Instruments & Supplies)
PeriodCompanyIndustry (mean)+/- 
MRQ1.0520.395+0.657
TTM0.9330.384+0.549
YOY0.6900.357+0.333
3Y0.7470.350+0.397
5Y0.6450.357+0.288
10Y0.6150.374+0.241
4.5.4.2. Debt to Equity Ratio

Measures if Akoya Biosciences Inc is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Akoya Biosciences Inc to the Medical Instruments & Supplies industry mean.
  • A Debt to Equity ratio of 0.0% means that company has $0.00 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Akoya Biosciences Inc:

  • The MRQ is 0.000. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM7.363-7.363
TTM7.363YOY2.393+4.971
TTM7.3635Y2.570+4.793
5Y2.57010Y2.448+0.122
Compared to industry (Medical Instruments & Supplies)
PeriodCompanyIndustry (mean)+/- 
MRQ-0.606-0.606
TTM7.3630.591+6.772
YOY2.3930.558+1.835
3Y3.8390.580+3.259
5Y2.5700.574+1.996
10Y2.4480.664+1.784
3rd party ad coffee SUPPORTERis ad-free.

4.6. Market Valuation

4.6.1. Earnings Per Share
4.6.2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Akoya Biosciences Inc generates.

  • Above 15 is considered overpriced but always compare Akoya Biosciences Inc to the Medical Instruments & Supplies industry mean.
  • A PE ratio of -1.11 means the investor is paying $-1.11 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Akoya Biosciences Inc:

  • The EOD is -1.029. Based on the earnings, the company is expensive. -2
  • The MRQ is -1.109. Based on the earnings, the company is expensive. -2
  • The TTM is -2.511. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-1.029MRQ-1.109+0.080
MRQ-1.109TTM-2.511+1.402
TTM-2.511YOY-4.267+1.756
TTM-2.5115Y-6.501+3.990
5Y-6.50110Y-6.192-0.310
Compared to industry (Medical Instruments & Supplies)
PeriodCompanyIndustry (mean)+/- 
EOD-1.02915.617-16.646
MRQ-1.10914.950-16.059
TTM-2.51114.998-17.509
YOY-4.26717.237-21.504
3Y-4.68818.333-23.021
5Y-6.50120.650-27.151
10Y-6.19220.725-26.917
4.6.2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Akoya Biosciences Inc:

  • The EOD is -2.172. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -2.340. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -3.890. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-2.172MRQ-2.340+0.168
MRQ-2.340TTM-3.890+1.550
TTM-3.890YOY-5.896+2.006
TTM-3.8905Y-6.910+3.020
5Y-6.91010Y-6.581-0.329
Compared to industry (Medical Instruments & Supplies)
PeriodCompanyIndustry (mean)+/- 
EOD-2.1729.966-12.138
MRQ-2.3409.091-11.431
TTM-3.8909.766-13.656
YOY-5.8969.099-14.995
3Y-6.2524.559-10.811
5Y-6.9105.094-12.004
10Y-6.5811.765-8.346
3rd party ad coffee SUPPORTERis ad-free.
4.6.2. Book Value per Share
4.6.2.1. Price to Book Ratio

Measures if the stock price of Akoya Biosciences Inc is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Medical Instruments & Supplies industry mean).
  • A PB ratio of -11.79 means the investor is paying $-11.79 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Akoya Biosciences Inc:

  • The EOD is -10.943. Based on the equity, the company is expensive. -2
  • The MRQ is -11.791. Based on the equity, the company is expensive. -2
  • The TTM is 4.623. Based on the equity, the company is fair priced.
Trends
Current periodCompared to+/- 
EOD-10.943MRQ-11.791+0.848
MRQ-11.791TTM4.623-16.414
TTM4.623YOY5.144-0.521
TTM4.6235Y4.744-0.121
5Y4.74410Y4.518+0.226
Compared to industry (Medical Instruments & Supplies)
PeriodCompanyIndustry (mean)+/- 
EOD-10.9432.454-13.397
MRQ-11.7912.397-14.188
TTM4.6232.562+2.061
YOY5.1442.695+2.449
3Y5.9842.743+3.241
5Y4.7443.519+1.225
10Y4.5183.925+0.593
4.6.2. Total Gains per Share

2.4. Latest News of Akoya Biosciences Inc

Does Akoya Biosciences Inc still have the same value as the quarterly reports suggest? Recent changes may be an indication that the value of the company is changing. Read the news from Akoya Biosciences Inc to keep up to date. Note: the news is often already included in the price.

DateTitleRead
2025-07-08
15:36
Quanterix completes acquisition of Akoya Biosciences, delisting set from NasdaqRead

4.7 Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of Akoya Biosciences Inc.

4.8.1. Institutions holding Akoya Biosciences Inc

Institutions are holding 69.798% of the shares of Akoya Biosciences Inc.

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2025-03-31Blue Water Life Science Advisors, LLC9.4196.4705469778500
2025-03-31BlackRock Inc3.23210.00011612002-25328-1.5469
2025-03-31Vanguard Group Inc2.783301388200-18862-1.3405
2025-03-31PARAGON Assoc & PARAGON Assoc II JV1.34542.1861671000-130000-16.2297
2025-03-31Geode Capital Management, LLC1.13680.000156698214930.264
2025-03-31State Street Corp0.9904937905796013.2988
2025-03-31JPMorgan Chase & Co0.82530411611363298751.9674
2025-03-31Nuveen, LLC0.78830.00483931833931830
2025-03-31UBS Group AG0.56530.0001281957196788231.0559
2025-03-31Peddock Capital Advisors, LLC0.47060.082623472000
2025-03-31Northern Trust Corp0.46360.0001231220-19123-7.6387
2025-03-31Verition Fund Managegment, LLC0.33350.00111663141663140
2025-03-31Morgan Stanley - Brokerage Accounts0.2280113698-16071-12.3843
2025-03-31Millennium Management LLC0.22710.00011132451132450
2025-03-31Virtu Financial LLC0.20450.00771019931019930
2025-03-31Goldman Sachs Group Inc0.20010997801947524.2513
2025-03-31Rhumbline Advisers0.14890.00017425542204131.6776
2025-03-31Charles Schwab Investment Management Inc0.1264063026240.0381
2025-03-31Deutsche Bank AG0.109805478800
2025-03-31Squarepoint Ops LLC0.10460.000152159521590
Total 23.70268.753511821708+1298752+11.0%

4.9.2. Funds holding Akoya Biosciences Inc

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2025-05-31Vanguard Total Stock Mkt Idx Inv1.76910.000188232100
2025-05-31iShares Russell 2000 ETF1.25410.001362546600
2025-05-31Vanguard Institutional Extnd Mkt Idx Tr0.61380.000430611200
2025-03-31Fidelity Small Cap Index0.53210.0015265400-5954-2.1942
2025-05-31iShares Russell 2000 Growth ETF0.50760.002925317100
2025-05-31Vanguard Russell 2000 ETF0.26530.001313234211660.8889
2025-05-31State St Russell Sm/Mid Cp® Indx SL Cl I0.24710.000412324700
2025-04-30Fidelity Extended Market Index0.24470.0004122070-1167-0.947
2025-05-31State St Russell Sm Cap® Indx SL Cl I0.13390.0016677600
2025-05-31Schwab Small Cap Index0.12630.00136300200
2025-05-31Xtrackers Russell 2000 ETF 1C0.10980.00455475800
2025-05-31iShares Micro-Cap ETF0.10890.00885431600
2025-03-31NT R2000 Index Fund - NL0.10760.001353674-2402-4.2835
2025-04-30Goldman Sachs Absolute Ret Trckr Instl0.09520.00084747327076.047
2025-03-31Extended Equity Market Fund K0.09310.0005464351420.3067
2025-03-31NT R2000 Index Fund - DC - NL - 30.0860.001342878-2869-6.2714
2025-05-31SPDR® Russell 2000 US Small Cap ETF0.08170.001440759-594-1.4364
2025-04-30Fidelity Total Market Index0.08120.00014049500
2025-05-31iShares Russell 2000 Small-Cap Idx Instl0.07630.00113805700
2025-03-31Russell 2000 Index Non-Lendable Fund E0.06930.001534562550.1594
Total 6.60310.03193293314-8916-0.3%

5.3. Insider Transactions

Insiders are holding 72.579% of the shares of Akoya Biosciences Inc.

DateOwnerTypeAmountPricePost Transaction AmountLink
2024-06-11Brian MckelligonSELL75002.08
2024-06-06Brian MckelligonSELL75002.01
2024-03-20Brian MckelligonSELL75004.97
2024-03-13Brian MckelligonSELL75004.94
2023-12-19Brian MckelligonSELL75004.48
2023-09-07Frederic PlaBUY200004.6
2023-06-12John Frederick EkBUY200005
2023-06-12Matthew WinklerBUY2033885
2023-06-06Brian MckelligonSELL50005.71
2022-12-14Joseph DriscollSELL2461312.54
2022-12-13Garry Ph.d. NolanSELL10013.25
2022-12-02Garry Ph.d. NolanSELL110013.25
2022-11-16Garry Ph.d. NolanSELL30013.25
2022-11-14Garry Ph.d. NolanSELL60013.28
2022-11-10Garry Ph.d. NolanSELL381013.31
2022-09-14Garry Ph.d. NolanSELL830513.26
2022-09-12Garry Ph.d. NolanSELL180013.3
2022-09-09Garry Ph.d. NolanSELL2219113.31
2022-09-07Brian MckelligonSELL500012.83
3rd party ad coffee SUPPORTERis ad-free.

5. Financial Statements




5.1. Reversals in quarterly reports

I have detected a reversal (positive to negative, negative to positive) in the following values of the quarterly reports.

 2024-03-312024-06-302024-09-302024-12-312025-03-31
Total Stockholder Equity 32,723-10,47422,249-8,61613,633-6,0387,595-13,484-5,889
Net Working Capital  68,636-11,86256,774-7,90648,868-1,58047,288-89,158-41,870



5.2. Latest Balance Sheet

Balance Sheet of 2025-03-31. Currency in USD. All numbers in thousands.

Summary
Total Assets112,649
Total Liabilities118,538
Total Stockholder Equity-5,889
 As reported
Total Liabilities 118,538
Total Stockholder Equity+ -5,889
Total Assets = 112,649

Assets

Total Assets112,649
Total Current Assets66,212
Long-term Assets46,437
Total Current Assets
Cash And Cash Equivalents 20,357
Short-term Investments 7,187
Net Receivables 11,742
Inventory 22,853
Other Current Assets 4,073
Total Current Assets  (as reported)66,212
Total Current Assets  (calculated)66,212
+/-0
Long-term Assets
Property Plant Equipment 12,086
Goodwill 18,262
Intangible Assets 13,845
Long-term Assets Other 2,244
Long-term Assets  (as reported)46,437
Long-term Assets  (calculated)46,437
+/-0

Liabilities & Shareholders' Equity

Total Current Liabilities108,082
Long-term Liabilities10,456
Total Stockholder Equity-5,889
Total Current Liabilities
Short-term Debt 79,701
Short Long Term Debt 76,487
Accounts payable 10,291
Other Current Liabilities 1,281
Total Current Liabilities  (as reported)108,082
Total Current Liabilities  (calculated)167,760
+/- 59,678
Long-term Liabilities
Capital Lease Obligations 7,236
Long-term Liabilities Other 3,512
Long-term Liabilities  (as reported)10,456
Long-term Liabilities  (calculated)10,748
+/- 292
Total Stockholder Equity
Common Stock2
Retained Earnings -301,088
Accumulated Other Comprehensive Income -1
Other Stockholders Equity 295,198
Total Stockholder Equity (as reported)-5,889
Total Stockholder Equity (calculated)-5,889
+/-0
Other
Capital Stock2
Cash and Short Term Investments 27,544
Common Stock Shares Outstanding 49,665
Current Deferred Revenue6,518
Liabilities and Stockholders Equity 112,649
Net Debt 63,366
Net Invested Capital 70,598
Net Working Capital -41,870
Property Plant and Equipment Gross 24,131
Short Long Term Debt Total 83,723



5.3. Balance Sheets Structured

Currency in USD. All numbers in thousands.

 Trend2025-03-312024-12-312024-09-302024-06-302024-03-312023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-31
> Total Assets 
0
0
0
77,660
74,481
206,342
195,411
190,907
187,128
184,263
176,457
176,031
154,297
188,879
177,244
180,369
154,750
143,745
129,973
125,005
112,649
112,649125,005129,973143,745154,750180,369177,244188,879154,297176,031176,457184,263187,128190,907195,411206,34274,48177,660000
   > Total Current Assets 
21,659
0
0
28,696
24,034
157,409
145,660
140,814
126,466
119,894
111,744
112,197
91,674
126,170
116,948
121,790
101,829
89,512
76,861
76,732
66,212
66,21276,73276,86189,512101,829121,790116,948126,17091,674112,197111,744119,894126,466140,814145,660157,40924,03428,6960021,659
       Cash And Cash Equivalents 
-21,659
0
0
17,006
11,691
135,464
120,150
113,079
93,938
46,881
51,836
74,229
60,247
93,328
78,595
83,125
13,039
8,923
12,557
11,779
20,357
20,35711,77912,5578,92313,03983,12578,59593,32860,24774,22951,83646,88193,938113,079120,150135,46411,69117,00600-21,659
       Short-term Investments 
43,318
0
0
0
0
0
0
0
0
40,725
29,868
6,989
0
0
0
0
48,536
36,301
23,339
23,261
7,187
7,18723,26123,33936,30148,53600006,98929,86840,7250000000043,318
       Net Receivables 
0
0
0
6,470
6,590
8,158
9,605
9,444
11,314
10,472
8,680
9,729
12,943
12,866
16,096
16,994
13,473
16,554
12,786
13,779
11,742
11,74213,77912,78616,55413,47316,99416,09612,86612,9439,7298,68010,47211,3149,4449,6058,1586,5906,470000
       Other Current Assets 
0
0
0
957
2,014
11,062
14,531
9,277
19,682
17,196
16,594
6,764
3,977
3,845
3,505
3,794
3,793
2,938
2,967
3,592
4,073
4,0733,5922,9672,9383,7933,7943,5053,8453,9776,76416,59417,19619,6829,27714,53111,0622,014957000
   > Long-term Assets 
-21,659
0
0
48,964
50,447
48,933
49,751
50,093
60,662
64,369
64,713
63,834
62,623
62,709
60,296
58,579
52,921
54,233
53,112
48,273
46,437
46,43748,27353,11254,23352,92158,57960,29662,70962,62363,83464,71364,36960,66250,09349,75148,93350,44748,96400-21,659
       Property Plant Equipment 
0
0
0
5,528
6,053
6,020
6,492
7,487
18,572
22,623
23,303
22,449
21,902
22,758
21,622
20,656
15,880
14,472
13,973
12,983
12,086
12,08612,98313,97314,47215,88020,65621,62222,75821,90222,44923,30322,62318,5727,4876,4926,0206,0535,528000
       Goodwill 
0
0
0
18,262
18,262
18,262
18,262
18,262
18,262
18,262
18,262
18,262
18,262
18,262
18,262
18,262
18,262
18,262
18,262
18,262
18,262
18,26218,26218,26218,26218,26218,26218,26218,26218,26218,26218,26218,26218,26218,26218,26218,26218,26218,262000
       Long Term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
3,496
3,399
0
0
003,3993,49600000000000000000
       Intangible Assets 
0
0
0
22,714
22,160
21,644
21,374
21,150
20,960
20,799
20,442
20,048
19,496
19,125
18,123
17,412
16,699
15,986
15,272
14,559
13,845
13,84514,55915,27215,98616,69917,41218,12319,12519,49620,04820,44220,79920,96021,15021,37421,64422,16022,714000
       Long-term Assets Other 
-21,659
0
0
2,460
3,470
2,706
3,322
3,194
2,566
2,685
2,706
3,075
2,963
2,564
2,289
1,550
1,380
1,313
5,605
2,469
2,244
2,2442,4695,6051,3131,3801,5502,2892,5642,9633,0752,7062,6852,5663,1943,3222,7063,4702,46000-21,659
> Total Liabilities 
0
0
0
59,089
134,481
58,521
58,019
69,556
80,576
93,413
101,369
117,450
112,173
116,978
115,271
126,599
122,027
121,496
116,340
117,410
118,538
118,538117,410116,340121,496122,027126,599115,271116,978112,173117,450101,36993,41380,57669,55658,01958,521134,48159,089000
   > Total Current Liabilities 
0
0
0
17,162
20,558
18,161
17,300
27,682
31,736
33,783
31,682
37,055
33,223
37,390
35,523
35,345
33,193
32,738
27,993
29,444
108,082
108,08229,44427,99332,73833,19335,34535,52337,39033,22337,05531,68233,78331,73627,68217,30018,16120,55817,162000
       Short-term Debt 
0
0
0
1,229
1,792
576
558
272
6,376
7,186
7,194
7,258
7,166
7,432
7,178
6,896
6,744
6,644
3,677
3,283
79,701
79,7013,2833,6776,6446,7446,8967,1787,4327,1667,2587,1947,1866,3762725585761,7921,229000
       Short Long Term Debt 
0
0
0
1,032
1,238
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
76,487
76,4870000000000000001,2381,032000
       Accounts payable 
0
0
0
5,074
5,776
4,898
4,071
23,198
11,518
13,372
8,172
10,628
8,683
11,732
11,890
11,776
10,747
9,785
8,760
8,759
10,291
10,2918,7598,7609,78510,74711,77611,89011,7328,68310,6288,17213,37211,51823,1984,0714,8985,7765,074000
       Other Current Liabilities 
0
0
0
7,015
8,874
8,400
8,317
-272
8,950
7,910
10,440
16,519
10,717
50,570
62,064
73,268
9,090
9,848
8,179
10,848
1,281
1,28110,8488,1799,8489,09073,26862,06450,57010,71716,51910,4407,9108,950-2728,3178,4008,8747,015000
   > Long-term Liabilities 
0
0
0
41,927
113,923
40,360
40,719
41,874
48,840
59,630
69,687
80,395
78,950
79,588
79,748
91,254
88,834
88,758
88,347
87,966
10,456
10,45687,96688,34788,75888,83491,25479,74879,58878,95080,39569,68759,63048,84041,87440,71940,360113,92341,927000
       Long term Debt Total 
0
0
0
0
33,388
32,256
32,363
32,471
32,576
42,565
52,714
63,277
63,455
63,636
0
0
0
0
0
0
0
000000063,63663,45563,27752,71442,56532,57632,47132,36332,25633,3880000
       Warrants
0
0
0
0
140,594
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000000140,5940000
       Other Liabilities 
0
0
0
0
9,839
7,777
8,356
9,403
8,310
7,278
7,558
8,240
7,258
7,633
0
0
0
0
0
0
0
00000007,6337,2588,2407,5587,2788,3109,4038,3567,7779,8390000
       Deferred Long Term Liability 
0
0
0
0
1,439
154
134
26
36
125
125
87
87
87
0
0
0
0
0
0
0
000000087878712512536261341541,4390000
> Total Stockholder Equity
34,188
0
0
18,571
-60,000
147,821
137,392
121,351
106,552
90,850
75,088
58,581
42,124
71,901
61,973
53,770
32,723
22,249
13,633
7,595
-5,889
-5,8897,59513,63322,24932,72353,77061,97371,90142,12458,58175,08890,850106,552121,351137,392147,821-60,00018,5710034,188
   Common Stock
0
0
0
2
1
2
2
2
2
2
2
2
2
2
2
2
2
2
2
0
2
202222222222222212000
   Retained Earnings -301,088-285,436-277,237-266,704-253,555-230,071-219,269-206,353-185,550-166,748-147,873-130,001-112,506-96,107-78,434-66,817-61,254-52,280000
   Capital Surplus 
0
0
0
0
0
214,636
215,824
217,456
219,056
220,941
223,025
225,333
227,672
278,252
0
0
0
0
0
0
0
0000000278,252227,672225,333223,025220,941219,056217,456215,824214,63600000
   Treasury Stock000000000000000000000
   Other Stockholders Equity 
0
0
0
-67,855
141,847
8,294
20,413
217,456
219,056
220,941
223,025
225,333
227,672
278,252
281,240
283,839
286,292
288,963
290,860
7,595
295,198
295,1987,595290,860288,963286,292283,839281,240278,252227,672225,333223,025220,941219,056217,45620,4138,294141,847-67,855000



5.4. Balance Sheets

Currency in USD. All numbers in thousands.




5.5. Cash Flows

Currency in USD. All numbers in thousands.




5.6. Income Statements

Currency in USD. All numbers in thousands.


5.7. Latest Income Statement

Income Statement (annual), 2024-12-31. Currency in USD. All numbers in thousands.

Gross Profit (+$)
totalRevenue81,672
Cost of Revenue-33,794
Gross Profit47,87847,878
 
Operating Income (+$)
Gross Profit47,878
Operating Expense-94,608
Operating Income-46,730-46,730
 
Operating Expense (+$)
Research Development19,745
Selling General Administrative69,317
Selling And Marketing Expenses0
Operating Expense94,60889,062
 
Net Interest Income (+$)
Interest Income2,506
Interest Expense-10,429
Other Finance Cost-0
Net Interest Income-7,923
 
Pretax Income (+$)
Operating Income-46,730
Net Interest Income-7,923
Other Non-Operating Income Expenses0
Income Before Tax (EBT)-55,219-38,241
EBIT - interestExpense = -55,219
-55,219
-44,936
Interest Expense10,429
Earnings Before Interest and Taxes (EBIT)-44,790-44,790
Earnings Before Interest and Taxes (EBITDA)-37,136
 
After tax Income (+$)
Income Before Tax-55,219
Tax Provision-146
Net Income From Continuing Ops-55,365-55,365
Net Income-55,365
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses122,856
Total Other Income/Expenses Net-8,4897,923
 

Technical Analysis of Akoya Biosciences Inc
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Akoya Biosciences Inc. The general trend of Akoya Biosciences Inc is UNKNOWN with 0.0% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Akoya Biosciences Inc's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator StateBullish trend Bearish trend
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Akoya Biosciences Inc Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Akoya Biosciences Inc.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

  • Between support/resistance: The price is trading between support and resistance lines.

The bullish price targets are: 1.39 < 1.43 < 1.44.

The bearish price targets are: 1.195 > 1.09 > 1.09.

Know someone who trades $AKYA? Share this with them.👇

Akoya Biosciences Inc Daily Support & Resistance Chart
3rd party ad coffee SUPPORTERis ad-free.

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Akoya Biosciences Inc. The current mas is .

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Akoya Biosciences Inc Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Akoya Biosciences Inc.

Akoya Biosciences Inc Daily Moving Average Convergence/Divergence (MACD) ChartAkoya Biosciences Inc Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Akoya Biosciences Inc. The current adx is .

Akoya Biosciences Inc Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Akoya Biosciences Inc.

Akoya Biosciences Inc Daily Parabolic SAR Chart
3rd party ad coffee SUPPORTERis ad-free.

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Akoya Biosciences Inc.

Akoya Biosciences Inc Daily Relative Strength Index (RSI) ChartAkoya Biosciences Inc Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Akoya Biosciences Inc.

Akoya Biosciences Inc Daily Stochastic Oscillator ChartAkoya Biosciences Inc Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Akoya Biosciences Inc.

Akoya Biosciences Inc Daily Commodity Channel Index (CCI) ChartAkoya Biosciences Inc Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Akoya Biosciences Inc.

Akoya Biosciences Inc Daily Chande Momentum Oscillator (CMO) ChartAkoya Biosciences Inc Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Akoya Biosciences Inc.

Akoya Biosciences Inc Daily Williams %R ChartAkoya Biosciences Inc Daily Williams %R Chart
3rd party ad coffee SUPPORTERis ad-free.

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Akoya Biosciences Inc.

Akoya Biosciences Inc Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Akoya Biosciences Inc.

Akoya Biosciences Inc Daily Average True Range (ATR) ChartAkoya Biosciences Inc Daily Average True Range (ATR) Chart
3rd party ad coffee SUPPORTERis ad-free.

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Akoya Biosciences Inc.

Akoya Biosciences Inc Daily On-Balance Volume (OBV) ChartAkoya Biosciences Inc Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Akoya Biosciences Inc.

Akoya Biosciences Inc Daily Money Flow Index (MFI) ChartAkoya Biosciences Inc Daily Money Flow Index (MFI) Chart
3rd party ad coffee SUPPORTERis ad-free.

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Akoya Biosciences Inc.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2025-02-18STOCH LONG EXITThe %K line crosses below the %D line.
2025-02-19STOCH SHORT EXITThe %K line crosses above the %D line.
2025-02-20STOCH LONG EXITThe %K line crosses below the %D line.
2025-02-21STOCH SHORT EXITThe %K line crosses above the %D line.
2025-02-24STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2025-02-25STOCH SHORT EXITThe %K line crosses above the %D line.
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2025-02-26MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2025-02-27STOCH LONG EXITThe %K line crosses below the %D line.
2025-02-28STOCH SHORT EXITThe %K line crosses above the %D line.
2025-03-03STOCH LONG EXITThe %K line crosses below the %D line.
2025-03-04STOCH SHORT EXITThe %K line crosses above the %D line.
2025-03-05WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2025-03-06STOCH LONG EXITThe %K line crosses below the %D line.
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2025-03-07STOCH SHORT EXITThe %K line crosses above the %D line.
2025-03-10STOCH LONG EXITThe %K line crosses below the %D line.
2025-03-11SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
2025-03-12MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2025-03-13STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-03-14STOCH SHORT EXITThe %K line crosses above the %D line.
2025-03-17RSI LONG ENTRY SHORT CLOSE30 crossover to upside
2025-03-18SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2025-03-21SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-03-24STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-03-26CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2025-03-27SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2025-03-28WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-03-31BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2025-04-02RSI LONG ENTRY SHORT CLOSE30 crossover to upside
2025-04-03MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-04-04STOCH SHORT EXITThe %K line crosses above the %D line.
2025-04-08STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2025-04-09RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-04-10STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-04-11MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2025-04-14SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2025-04-15STOCH LONG EXITThe %K line crosses below the %D line.
2025-04-16WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-04-21SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH SHORT EXITThe %K line crosses above the %D line.
2025-04-23SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-04-24WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-04-28STOCH LONG EXITThe %K line crosses below the %D line.
2025-04-30CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-05-02STOCH SHORT EXITThe %K line crosses above the %D line.
2025-05-05DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-05-06DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-05-08STOCH SHORT EXITThe %K line crosses above the %D line.
2025-05-09STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-05-12DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
2025-05-13MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-05-15STOCH SHORT EXITThe %K line crosses above the %D line.
2025-05-20MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2025-05-21DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2025-05-23STOCH LONG EXITThe %K line crosses below the %D line.
2025-05-30STOCH SHORT EXITThe %K line crosses above the %D line.
2025-06-03DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-06-06SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2025-06-09MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2025-06-10MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-06-11CCI LONG ENTRY SHORT CLOSE100 crossover to upside
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2025-06-12STOCH LONG EXITThe %K line crosses below the %D line.
2025-06-16STOCH SHORT EXITThe %K line crosses above the %D line.
2025-06-17STOCH LONG EXITThe %K line crosses below the %D line.
2025-06-18SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2025-06-20STOCH LONG EXITThe %K line crosses below the %D line.
2025-06-23STOCH SHORT EXITThe %K line crosses above the %D line.
2025-06-24STOCH LONG EXITThe %K line crosses below the %D line.
2025-06-25STOCH SHORT EXITThe %K line crosses above the %D line.
2025-06-26CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-06-27STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-06-30CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-07-01STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2025-07-03WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-07-07STOCH LONG EXITThe %K line crosses below the %D line.

6.3. Candlestick Patterns

Akoya Biosciences Inc Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Akoya Biosciences Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
OpenGreater thanClose1.290
Total0/1 (0.0%)
Penke
Good job! You gained 25 XP and 0   0   10 . What's next:
  • Share my analysis of Akoya Biosciences Inc with someone you think should read this too:
  • Are you bullish or bearish on Akoya Biosciences Inc? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Akoya Biosciences Inc? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Akoya Biosciences Inc

I send you an email if I find something interesting about Akoya Biosciences Inc.


Comments

How you think about this?

Leave a comment

Stay informed about Akoya Biosciences Inc.

Receive notifications about Akoya Biosciences Inc in your mailbox!

3rd party ad coffee SUPPORTERis ad-free.